On Wednesday, a Federal Circuit panel showed openness to Astellas Pharma’s argument for the removal of a Nebraska federal judge from its infringement case concerning the bladder medication, Myrbetriq. The pharmaceutical company contends that the judge has made statements indicating a potential bias against the industry, raising concerns about impartiality. However, the panel also emphasized the rarity and difficulty of reassigning judges in such circumstances.
Further details can be found in the original article.